A Phase 2a randomized controlled trial of the short term activity, safety and pharmacokinetics of a novel NNRTI, RDEA806 in HIV-1 positive, antiretroviral-naive subjects.
Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong V, Yeh LT, Quart B.
Antimicrob Agents Chemother. 2010 May 24.

A single-center cohort experience of raltegravir in salvage patients failing therapy.
Teague A, Scott C, Bower M, Gazzard B, Nelson M, Stebbing J.
J Acquir Immune Defic Syndr. 2010 Apr;53(5):666-7

Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
Gazzard B, Balkin A, Hill A.
AIDS Rev. 2010 Apr-Jun;12(2):67-75.

British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010
Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, Deacon-Adams C; BHIVA Viral Hepatitis Working Group
HIV Med. 2010 Jan;11(1):1-30

Changes in adherence and patients’ perceptions of treatment in a 48 week randomised study of continuation of zidovudine/lamividine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Cooper V, Moyle G, Fisher M, Reilly G, JEwan J, Liu H.C, Horne R for the SWEET group UK
AIDS Care 2010: in press

Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells
Page EE, Cox A, Atkins M, Nelson MR.
AIDS. 2010 Jun 1;24(9):1267-71

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, Nelson M.
Antiviral Res. 2010 May;86(2):224-6

Data linkage reduces loss to follow-up in an observational HIV cohort study.
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study Group.
J Clin Epidemiol. 2010 Mar 26.

Does earlier HIV RNA suppression provide long-term benefits?
Moyle G, Demasi R, Hill A.
AIDS 2010;24:1591-3

Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal
Falutz J, Mamputu J-C, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.
J Clin Endocrinol Metab 16 June 2010,

Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With
Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension.
Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.
J Acquir Immune Defic Syndr. 2010;53:311-22

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.
AIDS. 2010 Jan 2;24(1):55-65.

Epidemiology of herpes simplex virus types 2 and 1 amongst men who have sex with men (MSM) attending sexual health clinics in England and Wales: implications for HIV prevention and management
Hill C, McKinney E, Lowndes CM, Munro H, Murphy G, Parry JV, Gill ON and the GUM Anon Network*
Eurosurveillance in press.

eTriage – a novel, web-based triage and booking service: enabling timely access to sexual health clinics
R Jones, A Menon-Johansson, AM Waters, AK Sullivan
Int J STD & AIDS 2010;  21:30-33.

Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski AK.
AIDS. 2010 Mar 27;24(6):851-6

Febrile neutropenia in a HIV positive individual post-chemotherapy
Ridha E, Cookson H, Devitt E, Nelson M.
J Clin Virol. 2010 May;48(1):2-5. Epub 2010 Feb 18

Interventions to increase access to STI services: A study of England’s‘High Impact Changes’ across three central London clinics
Menon-Johansson A.S, Cohen C.E., Jones R., Nwokolo N., McOwan A., Barton S.E. & Sullivan A.K
STI 2010 in press

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.
Yilmaz S, Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L, Fletcher C, Back D, Pozniak A, Gazzard B, McGregor JL.
Genomics. 2010 Jul;96(1):57-65. Epub 2010 Mar 28.

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy
UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group
Clin Infect Dis. 2010 May 1;50(9):1275-85.

Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings
Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM, Dewolf F, Nelson M, Geretti AM, Larder BA
J Antimicrob Chemother. 2010 Apr;65(4):605-7

National Audit of Asymptomatic Screening in UK Genitourinary Medicine Clinics: Case notes audit.
H McClean , CA Carne, AK Sullivan, A Menon-Johansson, R Gokhale, G Sethi, AG Mammen-Tobin, D Daniels.
Int J STD & AIDS in press

National Audit of Asymptomatic Screening in UK Genitourinary Medicine Clinics: Clinic Policies Audit.
H McClean, CA Carne, AK Sullivan, A Menon-Johansson, R Gokhale, G Sethi, AG Mammen-Tobin, D Daniels.
Int J STD & AIDS in press

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study.
Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Wirtz V, Lataillade M, Absalon J, McGrath D; for the CASTLE Study Team
J Acquir Immune Defic Syndr. 2010;53:323-32

Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women.
Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, Ryan M, Nakabiito C, Back DJ, Khoo S, Merry C, Scarsi KK.
J Acquir Immune Defic Syndr. 2010 Jul 8.

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; DART Trial Team
Antimicrob Agents Chemother. 2010 Jul;54(7):2965-73.

Positive and negative drug selection pressures on the N3481 connection domain mutation: new insights from in vivo data
Price H,  Asboe D, Gazzard B, Fearnhill E. Pillay D, Dunn D:  UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study
Anitfir Ther. 2010: 15(2): 203-11.

Protein and Creatine Supplements and Misdiagnosis of Kidney Disease
Willis J, Jones R, Nwokolo N and Levy J
BMJ 2010;340:b5027

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study
Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.
J Acquir Immune Defic Syndr. 2010 Apr 24.

Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?
Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M, Danta M, Dusheiko G, Pybus O, Asboe D.
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):547-50. No abstract available. Erratum in: J Acquir Immune Defic Syndr. 2010 May 1;54(1):112

Spectrum of neurological disease in patients with discordant HIV-1 RNA levels in plasma and cerebrospinal fluid.
Scourfield A, Waters L, Nelson M.
J Infect. 2010 Mar;60(3):251-2

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
HIV-CAUSAL Collaboration
AIDS. 2010 Jan 2;24(1):123-37

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers
Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.
Antivir Ther. 2010;15:227-33.

The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.
on I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B, Nelson M, Stebbing J.
Antiviral Res. 2010 May;86(2):227-9

The impact of the 0-0 cell on measures of amino acid covariation
Dunn D, von Wyl V, Price H, Asboe D.
AIDS. 2010 Jan 2;24(1):159-60. No abstract available

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.
AIDS. 2010 Jan 16;24(2):223-30

Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort
Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.
Antivir Ther. 2010;15(2):267-79

Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A; UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency
HIV Med. 2010 Aug;11(7):432-8

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2.
Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J.
J Acquir Immune Defic Syndr. 2010 Aug 11

Unselected hepatitis C screening of men who have sex with men attending sexual health clinics
Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D
J Infect. 2010 May;60(5):351-3. Epub 2010 Feb 12.PMID: 20153770

Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P
J Infect Dis. 2010 Mar;201(5):720-9

A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis
Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M, Gazzard B, Nelson M
J Clin Gastroenterol. 2009 Sep 9.
`

A multicentre cohort experience with double-boosted protease inhibitors.
Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E, Gazzard B, Nelson M, Jones R.
J Antimicrob Chemother. 2009 Aug;64(2):434-5.

A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
Fisher M,  Moyle GJ, Shahmanesh  M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G for the SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK
Journal of Acquired Immune Deficiency Syndromes. 2009:51:562-568

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN
J Infect Dis. 2009 Sep 15;200(6):973-83.

Acute hepatitis C is not associated with abnormal fibroscan readings
Holmes P, Low E, Bower M, Anderson M & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 30

Advances in sexually transmitted infections of the gastrointestinal tract
Ng SC, Gazzard B.
Nat Rev Gastroenterol Hepatol. 2009 Aug 25

AIDS Kaposi’s sarcoma: outcomes in 254 consecutive patients diagnosed in modern times
Powles S, Weir J, Francis N, Newsom-Davis T, Crook T, Boffito M, Nelson M & Bower M.
HIV Medicine 2009, 10 (Suppl1), 10.

Antiretroviral rounds. Too many options?
Walmsley S, Wilkin T, Moyle G
AIDS Clin Care. 2009;21:13-5.

Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting
Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P
AIDS Read. 2009;19:22-31.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.
Br J Nutr. 2009 Jun 1:1-9.

Burkitt’s non-Hodgkin lymphoa presenting as an isolated Bell’s palsy in HIV-positive patients
Woodcock H, Holmes P, Powles S, Dunning J, Bower M & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 23

CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA
Haematologica. 2009 Jun;94(6):875-80

Clinical experience of raltegravir in salvage patients failing therapy, 48-week data
Teague A, Scott C, Bower M, Gazzard B & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 17

Clinical experience with maraviroc (UK 427857 or Celsentri) with an optimised background regimen in highly treatment-experienced patients.
Teague A, Underwood J, Scott C, Bower M, Gazzard B & Nelson M
HIV Medicine 2009, 10 (Suppl1), 18.

Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials
Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.
AIDS 2009: 23:1613.

Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P, Gazzard B, Nelson M, Stebbing J.
Blood. 2009 May 7;113(19):4521-4.

Darunavir/ritonavir once daily: a single-centre cohort experience
. Scott C, Teague A, Bower M, Gazzard B & Nelson M
HIV Medicine 2009, 10 (Suppl1), 8

Drug-drug interactions involving new antiretroviral drugs and drug classes.
Soodalter J, Sousa M, Boffito M
Curr Opin Infect Dis. 2009 Feb;22(1):18-27.

Effect of raltegravir on ALT in subjects coinfected with HIV and hepatitis C
ScourfieldA, Waters L, Randell PA, McCormick K, Armenis K, Bower M & Nelson M
HIV Medicine 2009, 10 (Suppl1), 31

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
Hill A, Sawyer W, Gazzard B.
HIV Clin Trials. 2009 Jan-Feb;10(1):1-12.

Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1 infected individuals.
Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM & Goodier MR.
AIDS 2009, 23: 29-34.

Excellent immunological recovery following the intensive chemotherapy CODOX-M?IVAC, an effective therapy for HIV_assocaited Burkitt’s lymphoma.
Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson M, Bower M & Cwynarski K.
HIV Medicine 2009, 10 (Suppl1), 5

Experience with ritoavir/atazanavir in HIV-positive antiretroviral naïve individuals commencing therapy
Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M & Nelson M.
HIV Medicine 2009, 10 (Suppl1), 18

FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease
Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, O’Doherty M & Bower M.
Eur J Nucl Med Imaging. 2009, 36: 648-52

Gastroenteropancreatic Neuroendocrine Tumors in Patients With HIV Infection: A Trans-Atlantic Series.
Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ
Am J Med Sci. 2009 Jan;337(1):1-4.

Highly active antiretroviral therapy and the incidence of Non-AIDS defining cancers in people with HIV infection
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H & Bower M
J Clin Oncol. 2009 Feb 20;27(6):884-90.

Highly active antiretroviral therapy and the incidence of non-AIDS defining cancers in people with HIV infection
Thomas Powles, David Robinson, Justin Stebbing, Mark Nelson, Brian Gazzard, Sundhiya Mandelia, Henrik Møller and Mark Bower
HIV Medicine 2009, 10 (Suppl1), 4

HIV testing in the UK
Gazzard B.
Lancet. 2009 Aug 1;374(9687):377

HIV opt out increases the offer and uptake of HIV tests in a GUM clinic
Price H, Sullivan AK
Int J STD AIDS. 2009 Jan;20(1):56-7.

Impact of recombinant human growth hormone on T-cell phenotype and function in vitro and in vivo during treated HIV-1 infection.
Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N
HIV Medicine 2009, 10 (Suppl1), 5.

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors
Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA, Moyle G, Linney A, Reilly G, Edwards S.
HIV Medicine 2009;10:351-5

Interruption of antiretroviral therapy is associated with increased plasma cystatin C
Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.
AIDS. 2009 Jan 2;23(1):71-82.

Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study.
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; on behalf of the UK Collaborative HIV Cohort (CHIC) Study
J Acquir Immune Defic Syndr. 2009 Jun 23.

Methylation reversal in high grade B-cell lymphoma cell lines identifies novel epigenetic changes conserved between immunocompetent and HIV-positive hosts and others specific to HIV-associated lymphomas.
Crook T, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Nelson M, Hatzimichael E & Bower M
HIV Medicine 2009, 10 (Suppl1), 4.

Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.
Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S.
J Infect Dis. 2009 Jun 15;199(12):1862-71.

Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A.
J Acquir Immune Defic Syndr. 2009 Jul 17

Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents
Coyne KM, Pozniak AL, Lamorde M, Boffito M
AIDS. 2009 Feb 20;23(4):437-46.

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.
J Antimicrob Chemother. 2009 Jun;63(6):1233-43. Epub 2009 Mar 28

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.
AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75.

Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B, McGregor JL, Shotliff K, Xiao H.
Vasc Health Risk Manag. 2009;5(1):287-300.

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.
Moyle G, Dejesus E, Boffito M, Wong RS, Gibney C, Badel K, Macfarland R, Calandra G, Bridger G, Becker S; X4 Antagonist Concept Trial Study Team.
Clin Infect Dis. 2009;48:798-805.

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST; OPTIMA Team1.
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9.

R